Computed tomography-based nomogram of Siewert type II/III adenocarcinoma of esophagogastric junction to predict response to docetaxel, oxaliplatin and S-1

Table 1 Demographic and clinical information of all enrolled patients receiving docetaxel, oxaliplatin and S-1

Variable		Training cohort (n = 94)	Validation cohort (n = 34)
Age, yr		66.0 ± 7.0	65 ± 6.1
Gender
	Male	77	20
	Female	17	14
cT stage
	cT3	62	16
	cT4	32	18
cN stage
	cN0	8	3
	cN1	36	13
	cN2	40	14
	cN3	10	4
Siewert type
	II	39	18
	III	55	16
GTV (cm3)		50.8 ± 32.0	51.1 ± 36.0

GTV: Gross tumor volume.

Table 2 Univariate analysis of possible prognostic factors associated with responses to docetaxel, oxaliplatin and S-1

Parameter		DCR	PD	P value
Sex				0.664
	Male	70 (82.4)	7 (77.8)
	Female	15 (17.6)	2 (22.2)
Age		66.0 ± 4.1	67.2 ± 3.9	0.728
cT stage				0.028
	cT3	57 (70.4)	5 (38.5)
	cT4	24 (29.6)	8 (61.5)
cN stage				0.351
	cN0	6 (10.2)	2 (5.7)
	cN1	7 (11.7)	29(82.9)
	cN2	37 (62.1)	3 (8.6)
	cN3	9 (15.2)	1 (2.8)
Siewert type				0.005
	II	29 (35.8)	10 (76.9)
	III	52 (64.2)	3 (23.1)
GTV (cm3)		47.3 ± 27.4	73.2 ± 54.3	0.040

The numbers in the parentheses are percentages. DCR: Disease control rate; PD: Progression disease; GTV: Gross tumor volume.